Sources | Names Used |
---|---|
CTRPv2 | sirolimus:bortezomib (250:1 mol/mol) |
PharmacoGx | sirolimus:bortezomib (250:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | TREML4 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.01 |
mRNA | MLANA | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
mRNA | RP11-668G10.2 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.01 |
mRNA | NLE1 | CTRPv2 | pan-cancer | AAC | -0.086 | 0.01 |
mRNA | POU1F1 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.01 |
mRNA | PRR11 | CTRPv2 | pan-cancer | AAC | -0.086 | 0.01 |
mRNA | E2F3 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
mRNA | RBBP4 | CTRPv2 | pan-cancer | AAC | 0.096 | 0.01 |
mRNA | FSD1L | CTRPv2 | pan-cancer | AAC | 0.083 | 0.01 |
mRNA | NR2F1 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |